Compare LEE & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEE | NYXH |
|---|---|---|
| Founded | 1890 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.1M | 152.8M |
| IPO Year | 2025 | 2021 |
| Metric | LEE | NYXH |
|---|---|---|
| Price | $8.72 | $3.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 34.3K | ★ 45.1K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $543,955,000.00 | N/A |
| Revenue This Year | $5.48 | $213.98 |
| Revenue Next Year | N/A | $126.25 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.34 | $2.76 |
| 52 Week High | $9.97 | $8.64 |
| Indicator | LEE | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 57.35 | 45.53 |
| Support Level | $8.07 | $2.78 |
| Resistance Level | $9.40 | $3.32 |
| Average True Range (ATR) | 0.47 | 0.19 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 83.50 | 42.35 |
Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.